The Johns Hopkins-created maps provide higher resolution and better coverage of gray matter than previously published maps, ...

If you are wondering whether Vertex Pharmaceuticals' current share price gives you a fair entry point, this article will walk ...

Imagine balancing a ruler vertically in the palm of your hand: you have to constantly pay attention to the angle of the ruler ...

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.

Moby Strategic Execution and Portfolio Expansion. Achieved 10% Q4 revenue growth driven by cystic fibrosis (CF) ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript February 12, 2026 Vertex Pharmaceuticals ...

When a cell divides, it performs a feat of microscopic choreography—duplicating its DNA and depositing it into two new cells.

Eli Lilly will shell out $2.4 billion to acquire genetic medicine developer Orna Therapeutics and has committed up to $8.85 billion to launch a seventh collaboration with Innovent Biologics. Both ...

We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its fourth-quarter and full-year 2025 results ...

SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license ...